Product Description
an orally administered PPAR_ modulator
Mechanisms of Action: PPAR-d Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Mitochondrial Myopathies *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Acute Respiratory Distress Syndrome|Healthy Volunteers|Kidney Diseases|Mitochondrial Myopathies|Muscular Dystrophy, Duchenne
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
0367-CL-1111 | P1 |
Completed |
Kidney Diseases |
2022-11-13 |
|
0367-CL-1103 | P1 |
Completed |
Mitochondrial Myopathies|Muscular Dystrophy, Duchenne|Acute Respiratory Distress Syndrome |
2022-04-30 |
|
0367-CL-1102 | P1 |
Completed |
Healthy Volunteers |
2022-01-11 |